Literature DB >> 25042874

Late onset hypogonadism of men is not equivalent to the menopause.

Farid Saad1, Louis J Gooren2.   

Abstract

Some men between the ages 45 and 60 years develop complaints and symptoms reminiscent of menopausal complaints in women. So, parallels were sought between the changes in female and male endocrinology during that period of life. Indeed, men do show a decline of serum testosterone from age 40 to 50 years onwards but it is a slow decline of 1-2% per year and over time it may amount to hypogonadism. The mechanism of a decline in serum testosterone in men does not resemble the menopause; it is partially an aging neuroendocrine system with a less efficient testosterone production but equally or more important, the result of inhibition of testosterone production by metabolic factors in relation to visceral obesity. These effects are in part reversible with weight loss. A hypogonadal state in aging men has deleterious effects. Mortality of all causes is highest in men with low testosterone impacting on their metabolic state leading to diabetes mellitus, cardiovascular disease, osteoporosis, and sexual dysfunction. Normalization of testosterone in aging hypogonadal men has a beneficial effect on the above pathologies. The fear that testosterone treatment of elderly men would lead to prostate disease has not been substantiated in studies. So, while men do not have a 'menopause', testosterone deficiency in old age deserves serious attention.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Drug safety; Late onset hypogonadism; Menopause; Testosterone

Mesh:

Substances:

Year:  2014        PMID: 25042874     DOI: 10.1016/j.maturitas.2014.06.016

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  3 in total

1.  Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men.

Authors:  Bruno Lunenfeld; George Mskhalaya; Michael Zitzmann; Stefan Arver; Svetlana Kalinchenko; Yuliya Tishova; Abraham Morgentaler
Journal:  Aging Male       Date:  2015-02-06       Impact factor: 5.892

Review 2.  Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review.

Authors:  Sandy Yeo; Katsiaryna Holl; Nicolás Peñaherrera; Ulrike Wissinger; Kate Anstee; Robin Wyn
Journal:  Clinicoecon Outcomes Res       Date:  2021-01-12

3.  Associations between smoking, sex hormone levels and late-onset hypogonadism in men differ depending on age.

Authors:  Qian Liu; Xiangchi Peng; Yiqun Gu; Xuejun Shang; Yuanzhong Zhou; Huiping Zhang; Liandong Zuo; Guangan Mei; Chengliang Xiong; Honggang Li; Xiangbin Kong
Journal:  Aging (Albany NY)       Date:  2021-02-01       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.